Legend Biotech Corp., a global biotechnology company developing novel therapies to treat life-threatening diseases, received its first approval from the U.S. FDA for CARVYKTI (ciltacabtagene autoleucel; cilta- cel), for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Legend Biotech entered into an exclusive worldwide...